19.12.2019,
3907 Zeichen
Corporate news transmitted by euro adhoc with the aim of a Europe-wide
distribution. The issuer is responsible for the content of this announcement.
Quarterly Report
Vienna -
Group revenue decreased by 2.7% to EUR 652.2 million\nEBITDA increased to EUR 60.4 million (after one-off effect), EBITDA margin to 9.3%\nImpairment loss in Medical Sector: EUR 46.8 million\nGroup EBIT after impairment loss in Medical Sector at EUR -13.7 million, EBIT margin at -2.1%\nAdjusted EBIT at EUR 29.0 million, adjusted EBIT margin at 4.4%\nEarnings after tax: EUR -34.1 million, adjusted EUR 8.6 million\nVienna/Austria, 19 December 2019 - The publicly listed Semperit Group
significantly improved the operating results with increasing profitability on
EBITDA level in the first three quarters of 2019, while revenue declined
slightly. In the first three quarters of 2019, total revenue recorded a year-on-
year decline of 2.7% to EUR 652.2 million.
EBITDA rose from EUR 41.9 million in the first three quarters of 2018 to EUR
60.4 million in the first three quarters of 2019. Adjusted for the one-off
effects, EBITDA rose from EUR 45.8 million in the past year(1) to EUR 56.4
million until the third quarter of 2019(2). The EBITDA margin rose from 6.3% to
9.3% in the first three quarters of 2019 and reflects the profitability improved
by the restructuring and transformation process (adjusted: 8.6% versus 6.8% in
the previous year). As a result, the aggregated value for 2018 was already
exceeded at the end of the third quarter.
Due to current information on the competitive situation of the medical business,
an impairment loss of EUR 46.8 million was recognized in the Medical Sector. The
background to this is the investment intensity of the significant competitors,
which increased beyond expectations through capacity expansion and production
automation, and the highly dynamic development of the market environment.
Despite Sempermed segment's progress regarding the improvement of operating
results, which is quicker than planned, it is to be expected that overcapacities
on the market and the resulting price pressure will affect the profitability in
a significantly negative manner.
Group EBIT improved to EUR -13.7 million in the first three quarters of 2019
from EUR -45.5 million in the previous year. EBITDA margin was -2.1% after -
6.8%. Adjusted for one-off effects(3), EBIT amounted to EUR 29.0 million
compared to EUR 17.5 million in the previous year. The adjusted EBIT margin
improved to 4.4.% versus 2.6% in the comparable period in the previous year.
Earnings after tax improved in the first three quarters of 2019 to EUR -34.1
million compared to EUR -72.9 million for the first three quarters of 2018.
Earnings per share amounted to EUR -1.66 compared with -3.68 in the same period
of 2018. Adjusted for one-off effects, the earnings after tax amounted to EUR
8.6 million compared with EUR -9.9 million in the same period of the previous
year.
1) Excluding the negative one-off effect of EUR 3.9 million from the closure of
the Sempertrans site in China for the first three quarters of 2018
2) Excluding the positive one-off effect of EUR 4.0 million from the reversal of
a provision for the tax proceedings on levies in Brazil
3) Q1-3 2019: reversal of a provision of EUR 4.0 million and impairment loss at
Sempermed of EUR 46.8 million; Q1-3 2018: EUR 3.9 million from the closure of
the Sempertrans site in China and impairment loss especially at Sempermed of EUR
55.2 million
end of announcement euro adhoc
issuer: Semperit AG Holding
Modecenterstrasse 22
A-1030 Wien
phone: +43 1 79 777-310
FAX: +43 1 79 777-602
mail: judit.helenyi@semperitgroup.com
WWW: www.semperitgroup.com
ISIN: AT0000785555
indexes: WBI, ATX PRIME, ATX GP
stockmarkets: Wien
language: English
Digital press kit: http://www.ots.at/pressemappe/2918/aom
BSN Podcasts
Christian Drastil: Wiener Börse Plausch
Wiener Börse Party #636: Marcel Hirscher läutet wieder die Opening Bell und ich denke dabei an Palfinger und Raiffeisen
Semperit
Akt. Indikation: 11.74 / 11.90
Uhrzeit: 23:00:16
Veränderung zu letztem SK: 0.17%
Letzter SK: 11.80 ( -0.84%)
Bildnachweis
1.
Markus Keller ist seit April 2017 Leiter des Segments Sempertrans; Bild: Semperit
, (© Aussendung) >> Öffnen auf photaq.com
Aktien auf dem Radar:Addiko Bank, Immofinanz, Marinomed Biotech, Flughafen Wien, Warimpex, EuroTeleSites AG, ATX Prime, ams-Osram, AT&S, Palfinger, RBI, Strabag, Pierer Mobility, UBM, CA Immo, Frequentis, Lenzing, SW Umwelttechnik, Oberbank AG Stamm, Wolford, Agrana, Amag, Erste Group, EVN, Kapsch TrafficCom, OMV, Österreichische Post, Telekom Austria, Uniqa, VIG, Wienerberger.
Croma
Croma Pharma® ist ein österreichisches Familienunternehmen mit Sitz in Leobendorf. Das Unternehmen ist auf die industrielle Fertigung von Hyaluronsäure-Spritzen spezialisiert und zählt in diesem Bereich europaweit zu den führenden Experten. Das Unternehmen setzt mit eigenen Marken auf die Wachstumssparte der minimalinvasiven ästhetischen Medizin.
>> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner
Mehr aktuelle OTS-Meldungen HIER